Power Law company profile

Kymera Therapeutics

Biotech & Life Sciences · Cambridge, United States · Founded 2016 · IPO 2020 Unicorn

A biotechnology company pioneering a transformative new approach to treating previously untreatable diseases

Valuation

$5.90B

Market cap · Apr/2026

Revenue

$39M

Latest reported FY

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026 $1B+ revenueColt · Power Law growth-stage

Investors

12 investors on Kymera Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 3 investors entered at this stage

Lilly Ventures

Atlas Venture

Amgen Ventures

Series B+ 9 investors entered at this stage

Bessemer Venture Partners

Janus Henderson Investors

Rock Springs Capital

BlackRock

BVF Partners

Wellington Management

6 Dimensions Capital

Bain Capital Life Sciences

Redmile Group

Global footprint

Where Kymera Therapeutics has talent and traffic

AI talent share

0.7% of workforce is AI talent
(2 of 291 staff)

Core AI10.34%

Other AI10.34%

Non-AI workforce28999.31%

Workforce by country

3 countries with
team presence

🇺🇸 United States98.5%

🇨🇦 Canada1%

🇲🇾 Malaysia0.5%

3 countries shown

Web traffic by country

25K monthly visits
across markets

🇺🇸 United States63.2%

🇮🇳 India11.2%

🇪🇸 Spain7.2%

🇬🇧 United Kingdom6%

🇨🇦 Canada5.6%

Top 5 markets shown

Patent intelligence

$26M patent portfolio · 107 active families

Estimated portfolio value

$26M

0.44% of market cap · 2.2× the top peer Gracell Biotechnologies ($12M)

107 active patent families

Where Kymera Therapeutics innovates BiochemistryOrganic chemistryCombinatorial chemistryPharmacologyMolecular biology

Where Kymera Therapeutics concentrates vs peers

Each axis is a top-10 topic across Kymera Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Kymera Therapeutics

An AI-synthesized read of the highest-engagement posts about Kymera Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Kymera Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles